

Preoperative Diagnosis of Upper Gastrointestinal Leiomyoma by Endoscopic Ultrasound-Guided Fine Needle Aspiration

ABSTRACT

Aims: To evaluate the role of endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) with using immunohistochemical analysis in the preoperative diagnosis of upper gastrointestinal leiomyoma.

Study design: This was 'prospective' observational study.

Place and Duration of Study: Department of surgery №1, Vinnytsia National Pirogov Medical University, Vinnytsia, Ukraine; between September 2016 and February 2019.

Methodology: sixteen prospectively studies have been performed using endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) in patients with submucosal hypoechoic tumors (according to the results of previous gastroduodenoscopy) with continuity to proper muscle layer suspected as leiomyoma of upper gastrointestinal tract. All cases for the final diagnosis underwent surgery (n = 16). Additionally, immunophenotyping of specimens obtained by EUS-FNA and surgical resection specimens have been compared.

Results: The puncture has been performed in all patients without any anatomical problems. The collection rate of adequate specimens from the GI tract subepithelial hypoechoic tumor with continuity to proper muscle layer was 87, 5%. The diagnostic rate for the tumor less than 2 cm, 2 to 4 cm, and 4 cm or more were 77, 8%, 100% and 100% respectively. In 16 surgically resected cases, the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of EUS-FNA using immunohistochemical analysis of leiomyoma were 100%; 83,3%; 90,9%; 100% and 93,75% respectively. No major complications were encountered.

Conclusion: EUS-FNA with immunohistochemical analysis is a safe and accurate method in the preoperative diagnosis of gastrointestinal leiomyoma. It should be taken into consideration in decision making, especially in early diagnosis following minimal invasive surgery for gastrointestinal leiomyoma.

11
12 *Keywords:* Gastrointestinal leiomyoma, Endoscopic ultrasound-guided fine needle
13 *aspiration, Immunohistochemical analysis, Gastrointestinal stromal tumor.*
14

1. INTRODUCTION

15
16
17 Leiomyomas of the gastrointestinal tract (GI tract) were selected as a separate group of non-
18 epithelial benign tumors in 1983. The tumors of this group have specific histological and
19 immunohistochemical features. Leiomyomas are the most common benign non-epithelial
20 tumors of the GI tract, and according to various literary references, compose up to 75% of
21 them in the esophagus, up to 56% in the stomach, and up to 48% in the duodenum [1-4].
22 Macroscopically, the tumor grows in the form of a spherical node, originating from the
23 mucosal muscular plate or from the muscularis propria of the wall of the gastrointestinal
24 tube. However, not all tumors of the GI tract, which originate from the muscular layer of the
25 wall, are leiomyomas and have a benign nature of the disease. Among such tumors are a

26 gastrointestinal stromal tumor (GIST), leiomyosarcomas, neurofibromas, adenocarcinomas,
27 and others. Therefore, it is very important to establish the accurate pathohistological
28 diagnosis for the proper medical treatment and the choice of optimal options of surgical
29 intervention in various diseases. This problem stays especially relevant for the preoperative
30 diagnosis of GIST and leiomyomas [5-9]. Performing an ordinary endoscopic study with
31 using forceps biopsy is often non-informative, because the submucosal tumors (SMT) of the
32 GI tract are usually covered with a normal mucous membrane, and this fact prevent the right
33 selection of informative biological material for the study of deeply placed tissues [10].

34 The data from previous studies indicate, that endoscopic ultrasonography (EUS) allows
35 intramural imaging of the GI tract, and is useful both for the diagnosis of various SMTs, and
36 for the differential diagnosis of SMT with extraluminal lesions of the gastrointestinal tract [11-
37 16]. However, the diagnosis on the basis of EUS is preliminary and cannot compete in
38 accuracy with the final diagnosis on the basis of histological and immunohistochemical
39 results. Thus, the final differential diagnosis of SMT of the GI tract is not possible without
40 performing surgical intervention. Therefore, the search for a less invasive method for
41 establishment the final diagnosis of SMT of GI tract is relevant.

42 The Endoscopic Ultraonography-guided Fine Needle Aspiration biopsy (EUS-FNA) has
43 become the minimal invasive technique that allows the identification and differentiation of
44 various types of submucosal neoplasms of the GI tract [17-26]. In accordance to the current
45 requirements for final diagnosis, the diagnosis of leiomyomas of GI tract should be based on
46 immunohistochemical analysis results. It is the best method that allows establishing the
47 accurate final diagnosis.

48 We here attempted to determine the diagnostic value of the Endoscopic Ultraonography-
49 guided Fine Needle Aspiration biopsy (EUS-FNA) with using immunohistochemical analysis
50 for preoperative diagnosis of GI tract leiomyomas.

51

52 2. MATERIAL AND METHODS

53

54 From September 2016 to February 2019, 16 prospectively diagnostic studies using
55 endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) were performed in
56 patients with suspicion of subepithelial gastrointestinal neoplasms (based on previous
57 endoscopy).

58 These were patients with subepithelial hypoechoic tumors, located in the second or fourth
59 endosonographic layers of the gastrointestinal wall, homogeneous, with well-defined edges,
60 and without signs of malignancy (according to endosonography). There were 9 women
61 (56%) and 7 men (44%). The average age of patients was 56 years (from 31 to 80 years).
62 The informed written consent for the study and treatment was obtained from all the patients.

63 Diagnostic Endoscopic Ultrasonography-guided Fine Needle Aspiration (EUS-FNA) was
64 performed on an outpatient's basis, in a private diagnostic center. First, with the patient
65 under conscious sedation, a standard endoscopic sonography was performed using
66 conventional radial scanner echoendoscope GF-UM20 (Olympus, Tokyo, Japan). EUS-FNA
67 was performed on a one-day inpatient basis, with conscious sedation, using the GF-
68 UCT160P-OL5 convex array echoendoscope (Fig. 1).

69 The echoendoscope was connected to a Toshiba ultrasound scanner SSA-550A (Toshiba,
70 Tokyo, Japan). Color flow and Doppler sonography were performed to exclude intervening
71 vascular structures and to select a vessel-free needle track. All FNA procedures were

72 performed using the Olympus needle (NA-11J-KB) consisting of a 180 cm long steel needle
73 0.8 mm in diameter (22 G), with a stylet passing through a metal catheter with an outer
74 diameter of 1.6 mm. The needle **was** inserted into the working channel of the
75 echoendoscope. Once the tip of the catheter was visualized, the needle was advanced from
76 the catheter sheath through the wall of the GI tract and into the target lesion under
77 ultrasonographic guidance (Fig. 2). After that the stylet was removed and continuous suction
78 applied with a 20-mL syringe. The needle was moved back and forth within the lesion under
79 ultrasonographic guidance. When a sufficient amount of biological material **was** selected, the
80 suction was then released and the needle removed from the biopsy channel. The aspirates
81 were placed on glass slides, and both air-dried and alcohol-fixed smears were prepared. **The**
82 air dried smears were stained with a modified Giemsa stain and reviewed immediately by a
83 cytopathologist on site to ensure specimen adequacy. All received biological samples were
84 sent to the pathology laboratory for further evaluation using histological and
85 immunohistochemical methods.

86 Another group of histological specimens obtained later during operative intervention was
87 also sent to the pathology laboratory for their evaluation by the same methods of diagnosis.


88 Both the EUS-FNA and surgical resection specimens were fixed in 10% formaldehyde, the
89 volume of which was 10-20 folds larger than the volume of the placed material, and left to fix
90 for at least 48 hours. Then, the tissue blocks were embedded in paraffin. The prepared
91 sections thicknesses of 5-7 μm were stained with hematoxylin-eosin and by Van Gieson.
92 The histologic study of leiomyomas was performed using an ocular micrometer by
93 **OLYMPUS** BX41 light microscope with magnifications of 100, 200 and 400 power.

94 The polymer method was used for immunohistochemical staining with the following
95 antibodies: c-kit (polyclonal, 1: 200; Dako North America Inc., Carpinteria CA, USA), CD34
96 (QBend 10, monoclonal, 1: 100; Novocastra, Benton Lane, UK); smooth muscle actin (1A4,
97 monoclonal, 1: 100; Dako A / S, Glostrup, Denmark), S-100 (polyclonal, 1:12; Dako A / S,
98 Glostrup, Denmark). A tumor with a positive response to c-kit and / or CD34 was diagnosed
99 as GIST. A tumor with a negative reaction to c-kit, CD34, S-100, and positive for SMA was
100 diagnosed as leiomyoma. EUS-FNA diagnoses obtained by using immunohistochemical
101 analysis were analyzed for the correlation with final diagnoses, which were based on the
102 results of an immunohistochemical examination of surgically resected pathology materials.
103



104
105

Fig. 1. Echoendoscope GF-UCT160P-OL5



106

107 **Fig. 2. Steps of the EUS-FNA study:** A: Submucosal lesion in the angulus of the stomach shown
 108 on endoscopy; B: EUS using ultrasound catheter probe reveals 3 cm subepithelial hypoechoic tumor
 109 with continuity to proper muscle layer (arrow-mp); C: Puncture of submucosal lesion under direct
 110 endosonographic visualization. The needle can be visualized; D: EUS-FNA smear, showing a small
 111 tissue fragment composed of ovoid to spindle-shaped nuclei without signs of atypia (modified Giemsa
 112 stain).

113

114

115 3. RESULTS

116

117 All the patients in our study group have been diagnosed with SMT of the GI tract according
 118 to the results of previous gastroduodenoscopy, that had prompted their referral for EUS-FNA
 119 for tissue diagnosis. The anatomical localization of subepithelial tumors of the GI tract of 16
 120 patients are summarized in Table 1. The puncture was performed in all 16 patients; there
 121 were no anatomical impediments to its execution. The collection rate of adequate specimens
 122 was 87.5% (14/16). When the selected specimen was recognized as non-informative, the
 123 puncture was repeated. We encountered no complications associated with this procedure.
 124 The diagnostic rate of EUS-FNA, according to the tumor size is shown in Table 2. When the
 125 size of the tumors was classified into three grades, depending on their size (the interval
 126 between the grades sizes was 2-cm), a clear statistical trend was observed: the larger the
 127 size of the tumor, the higher the rate of diagnosis. For tumors, with size less than 2 cm,
 128 the diagnostic rate was 77.8% (the number of informative specimens, that were obtained at the
 129 first attempt of a puncture in one patient). When the size of the tumor was greater than 2cm,
 130 the diagnostic rate for them was 100%. After performing EUS-FNA, all the patients in the
 131 study group had undergone surgical interventions. Table 3 shows all types of surgical
 132 interventions performed in patients of our study group. The results of the
 133 immunohistochemical analysis of specimens, obtained by EUS-FNA compared with the
 134 results of immunohistochemical analysis of specimens, obtained after surgical resections are
 135 shown in Table 4. According to the obtained results, the effectiveness value of using a
 136 research method such as EUS-FNA in the diagnosis of leiomyoma of the GI tract was

137 determined. The distribution of the results of the study is reflected in the table 5. Calculated
 138 the rates of diagnostic sensitivity, specificity, positive predictive value, negative predictive
 139 value, and diagnostic accuracy of this method of study. The overall diagnostic accuracy of
 140 EUS-FNA using immunohistochemical analysis of leiomyoma of the GI tract was 93.75%,
 141 diagnostic sensitivity was 100%, diagnostic specificity was 83.3%, positive predictive value
 142 was 90.9%, negative predictive value was 100 %.

143

144 **Table 1. Anatomical localization of subepithelial tumors of the gastrointestinal tract in**
 145 **patients our study group according to endosonography**

Anatomical localization of tumors	Number (Total = 16)	Percentage ratio
Esophagus	8	50%
stomach	7	43.75%
duodenum	1	6.25%

146

147

148 **Table 2. Diagnostic rate according to tumor size**

Tumor size	Diagnostic rate, n (%)
0-2 cm	5/7 (77,8%)
2-4 cm	6/6 (100%)
> 4 cm	3/3 (100%)
Total diagnostic rate (%)	14/16 (87,5%)

149

150 **Table 3. Types of surgical interventions performed in patients study group (n = 16)**

Type of surgical interventions	Number of performed surgical interventions
Submucosal endoscopic dissection of esophageal leiomyomas	5
Thoracoscopic enucleation of esophageal leiomyomas	2
Laparoscopic proximal resection of the stomach	1

Laparoscopic enucleation of leiomyomas of the stomach	2
Laparoscopic sectoral resection of the stomach	3
Resection of the stomach by Billroth II	2
Resection of the duodenum with Roux-en-Y gastro-entero anastomosis	1

151

152

153 **Table 4. The results of immunohistochemical analysis of biological specimens**

Biological specimens, obtained via EUS-FNA		Biological specimens, obtained by surgical resection	
Leiomyoma	11	Leiomyoma	10
GIST	4	GIST	5
schwannoma	1	schwannoma	1

154

155

156 **Table 5. Leiomyoma diagnosis using EUS-FNA with immunohistochemical analysis**
 157 **among other subepithelial tumors of gastrointestinal tract (n = 16)**

158

	EUS-FNA with immunohistochemical analysis	
	Leiomyoma	Other subepithelial tumors
Leiomyoma	10	0
Other subepithelial tumors	1	5

159

160

161

162

163

164 4. DISCUSSION

165

166 Gastrointestinal Leiomyomas remain among the least studied benign non-epithelial
167 neoplasms. The rarity of this pathology does not allow us to accumulate enough information
168 to determine the precise tactics of diagnosis and treatment of this type of tumors [1-3]. In
169 addition, leiomyomas should be differentiated with other submucosal lesions of the
170 gastrointestinal tract, especially with GIST, because, despite of similarity in these two types
171 of tumors, GIST is a potentially malignant tumor, and the management for these two
172 diseases will be different [4-5]. The problem of the final identification of GISTs and their
173 differential diagnosis with leiomyoma was finally facilitated with the onset of using the
174 immunohistochemical method. This method identifies the c-kit proto-oncogene product,
175 which is overexpressed in nearly all GISTs and distinguishes these neoplasms from
176 leiomyomas, leiomyosarcomas, lipomas, schwannomas, or other GI tumors [6-9].

177 Since all these tumors have submucosal location in the gastrointestinal wall, accurate
178 diagnosis with using of a conventional endoscopic study is not possible. Since the
179 endosonography has begun to be used as a diagnostic method in clinical practice, the
180 diagnostic situation with SMTs of the GI tract, in particular leiomyomas, has changed
181 significantly [10]. By performing endosonography, the five-layer structure of the GI tract wall
182 is clearly visualized. According to various endosonographic imaging, we can predict the
183 nature of submucosal neoplasm; determine its size and level of its origin [11-12]. At the
184 endosonographic study, leiomyoma looks like a homogeneous hypoechoic lesion, with well-
185 defined edges, which derives from the second or fourth endosonographic layers (Fig. 3).
186 According to literature data [10-16], the diagnostic specificity of the endosonography for the
187 gastrointestinal tract exceeds other noninvasive imaging methods, such as transabdominal
188 ultrasound, radiography and computed tomography of the GI tract.

189 However, the above mentioned submucosal tumors of the GI tract may have similar
190 echogenic signs and cannot be accurately diagnosed without histological and
191 immunohistochemical examination. Accurate preoperative histological and
192 immunohistochemistry diagnosis [5-9] can directly influence the choice of treatment for these
193 diseases. All non-invasive diagnostic methods do not allow establishing the precise
194 pathohistological diagnosis and differentiating GIST from gastrointestinal leiomyoma. Even
195 those non-invasive diagnostic methods, criteria of which demonstrate the best correlation
196 help only to predict the nature of the submucosal neoplasm and the degree of its
197 malignancy. For example, endoscopy alone has suboptimal accuracy of as low as 40% for
198 identifying the cause of submucosal bulges [11-13]. Usually the mucosal surface is normal,
199 and conventional forceps biopsy results are frequently negative. Other noninvasive imaging
200 methods such as transabdominal ultrasound and computed tomography are also suboptimal
201 for evaluating submucosal indentations [14].

202 EUS combines the endoscopic view with ultrasonographic images generated by a high-
203 frequency intraluminal probe. This allows clear imaging of the gastrointestinal wall layers and
204 precise evaluation of the submucosal tumor whether from extrinsic compression or the layer
205 in which the intramural lesion originates. Although EUS provides important morphologic
206 information from submucosal lesions, including some features suggestive of malignancy
207 (size > 3-4 cm, irregular margins, internal echogenic foci or cystic spaces, and rapid growth
208 rate at follow-up EUS) [11-16], this method cannot establish a final pathologic diagnosis.

209 One of the alternative diagnostic methods in this situation is EUS-FNA, and according to
210 recent studies, this method has been used increasingly for the evaluation of various tumors
211 located in the GI tract [17-20]. Observations to date indicate that EUS-FNA is a safe and
212 accurate diagnostic procedure. However, most of the results of previous studies were related
213 to the diagnosis of pancreatic lesions and lymphadenopathy. In addition, the diagnostic
214 value of EUS-FNA for the diagnosis of leiomyoma of the GIT was not determined in previous
215 studies [21-26]. The ability to determine the level of origination of gastrointestinal
216 leiomyomas using endosonography will directly affect the surgical treatment options, which

217 will be different at various localization of this type of tumors. Typically, leiomyoma, which
218 originates from the muscular plate of the mucosal membrane, can be treated by endoscopic
219 resection, while such a method of treatment is contraindicated for leiomyomas, which
220 originate from the muscularis propria of the hollow organ's wall. Incorrectly chosen surgery
221 can lead to perforation of the GI tract [27-32].

222 In our study, 5 patients with leiomyomas of the esophagus, which derived from the mucosal
223 muscular plate, were operated. Complications, such as bleeding or perforation of the wall did
224 not occur. This indicates that endosonography is very useful for the choice of technique and
225 options of surgical intervention for patients with gastrointestinal leiomyomas. This method
226 makes the treatment of gastrointestinal leiomyomas more safe, rational and economic.

227 In our study, the collection rate of adequate specimens from a GI tract subepithelial
228 hypoechoic tumor using EUS-FNA was 87.5%. The diagnostic rate of this method of study,
229 depending on the size of the tumor, was 77.8% for tumors less than 2 cm and 100% for
230 neoplasms with size greater than 2 cm. The overall diagnostic accuracy of EUS-FNA using
231 immunohistochemical analysis of leiomyoma of the GI tract was 93.75%, compared with the
232 immunohistochemical results of surgically resected specimens. According to previous
233 studies, accuracy of preoperative diagnosis of EUS-FNA using immunohistochemical
234 analysis ranged from 91% to 100% [17-26], which coincides with the data of our study. This
235 method allows precise preoperative and differential diagnosis of submucosal tumors of the
236 GI tract, which facilitates the choice of the optimal treatment and surgical option
237 management.
238



239 **Fig. 3. EUS-FNA leiomyoma of the stomach.** A- appearance of leiomyomas in the stomach
240 during endoscopic examination; B- EUS- visualization of the lesion, which is located in the fourth
241 endosonographic layer of the stomach wall; C- EUS-FNA of lesion, needle marked with arrow; D-
242 histological specimen of EUS-FNA.
243

244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294

5. CONCLUSION

Our study confirms the important role of EUS-FNA using immunohistochemical assays to evaluate submucosal lesions of the gastrointestinal tract. This technique is absolutely safe and according to its results, the treatment tactics and the planned surgical management options can be considerably altered. Also, according to EUS-FNA results using immunohistochemical analysis, it is possible to establish a final pathologic diagnosis without performing surgical resection, which is important for oncologists before any chemotherapy, radiation therapy, and palliative treatment.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

CONSENT

Informed consents **have been** sought and obtained from all the patients.

ETHICAL APPROVAL

Ethical approval **has been** obtained from institutional and university ethical research cell committee.

REFERENCES

1. Akahoshi K, Sumida Y, Matsui N, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. *World J Gastroenterol.* 2007; 13(14):2077–2082. doi:10.3748/wjg.v13.i14.2077.
2. Kohli DR, Faigel DO. Esophageal leiomyomas: making mole hills out of mole hills. *Gastrointest Endosc.* 2018; 87(2):378–379. doi: 10.1016/j.gie.2017.08.028.
3. Jiang, W., Rice, T.W., and Goldblum, J.R. Esophageal leiomyoma: experience from a single institution. *Dis Esophagus.* 2013 Feb-Mar;26(2):167-74. doi: 10.1111/j.1442-2050.2012.01345.x.
4. Lee, L.S., Singhal, S., Brinster, C.J. et al. Current management of esophageal leiomyoma. *J Am Coll Surg.* 2004; 198: 136–146. DOI: 10.1016/j.jamcollsurg.2003.08.015
5. Tsai, S.-J., Lin, C.-C., Chang, C.-W. et al. Benign esophageal lesions: endoscopic and pathologic features. *World J Gastroenterol.* 2015 Jan 28;21(4):1091-8. doi: 10.3748/wjg.v21.i4.1091.
6. Faigel, D.O. and Abulhawa, S. Gastrointestinal stromal tumors: the role of the gastroenterologist in diagnosis and risk stratification. *J Clin Gastroenterol.* 2012 Sep;46(8):629-36. doi: 10.1097/MCG.0b013e3182548f6c.
7. Stelow, E.B., Jones, D.R., and Shami, V.M. Esophageal leiomyosarcoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration. *Diagn Cytopathol.* 2007; 35: 167–170. PMID: 17415921
8. Vesna Janevska, Adelina Qerimi, Neli Basheska, Elena Stojkova, Vlado Janevski, Rubens Jovanovic, Julija Zhivadinovik, Liljana Spasevska. Superficial leiomyomas of the gastrointestinal tract with interstitial cells of Cajal. *Int J Clin Exp Pathol.* 2015; 8(12): 15977–15984.

- 295 9. Nilam Virani, Judy Pang, and Madelyn Lew (2016) Cytologic and
296 Immunohistochemical Evaluation of Low-Grade Spindle Cell Lesions of the
297 Gastrointestinal Tract. Archives of Pathology & Laboratory Medicine: October 2016,
298 Vol. 140, No. 10, pp. 1038-1044. <https://doi.org/10.5858/arpa.2016-0235-RA>.
- 299 10. Shen EF, Arnott ID, Plevris J, Penman ID. Endoscopic ultrasonography in the
300 diagnosis and management of suspected upper gastrointestinal submucosal
301 tumours. *Br J Surg.* 2002; 89:231-235.
- 302 11. Wang Y, Sun Y, Liu Y, Li Y, Wang Z. Transesophageal intraluminal
303 ultrasonography in diagnosis and differential diagnosis of esophageal leiomyoma.
304 *Zhonghua Yixue Zazhi.* 2002;82:456-458
- 305 12. Gress F, Schmitt C, Savides T, Faigel DO, Catalano M, Wassef W, Roubein L, Nickl
306 N, Ciaccia D, Bhutani M. Interobserver agreement for EUS in the evaluation and
307 diagnosis of submucosal masses. *Gastrointest Endosc.* 2001; 53:71-76.
- 308 13. Rösch T, Kapfer B, Will U, Baronius W, Strobel M, Lorenz R, Ulm K. Accuracy of
309 endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a
310 prospective multicenter study. *Scand J Gastroenterol.* 2002; 37:856-862.
- 311 14. Christian Pesenti, Erwan Bories, Fabrice Caillol, Jean Philippe Ratone, Sebastien
312 Godat, Genevieve Monges,1 Flora Poizat,1 Jean Luc Raoul,2 Pauline Ries,2 and
313 Marc Giovannini. Characterization of subepithelial lesions of the stomach and
314 esophagus by contrast-enhanced EUS: A retrospective study. *Endosc Ultrasound.*
315 2019 Jan-Feb; 8(1): 43–49. doi: 10.4103/eus.eus_89_17
- 316 15. Standards of Practice Committee, Faulx AL, Kothari S, Acosta RD, Agrawal D,
317 Bruining DH, Chandrasekhara V, Eloubeidi MA, Fanelli RD, Gurudu SR, Khashab
318 MA, Lightdale JR, Muthusamy VR, Shaukat A, Qumseya BJ, Wang A, Wani SB,
319 Yang J, DeWitt JM. The role of endoscopy in subepithelial lesions of the GI tract.
320 *Gastrointest Endosc.* 2017 Jun; 85(6):1117-1132. doi: 10.1016/j.gie.2017.02.022
- 321 16. Nesje LB, Laerum OD, Svanes K, Ødegaard S. Subepithelial masses of the
322 gastrointestinal tract evaluated by endoscopic ultrasonography. *Eur J Ultrasound.*
323 2002; 15:45-54.
- 324 17. Attila T1, Aydın Ö2. Lesion size determines diagnostic yield of EUS-FNA with onsite
325 cytopathologic evaluation for upper gastrointestinal subepithelial lesions. *Turk J*
326 *Gastroenterol.* 2018 Jul; 29(4):436-441. doi: 10.5152/tjg.2018.17876.
- 327 18. Lopes CV, Rigon P, Zettler CG, Hartmann AA. Differential diagnosis of
328 mesenchymal neoplasms of the digestive tract by cell block and
329 immunohistochemistry. *Cytopathology.* 2018 Dec;29(6):531-536. doi:
330 10.1111/cyt.12630.
- 331 19. Rohit M, Bhatt A, Cruise M, Wearsch PA, Goldblum JR, Sturdis CD. Endoscopic
332 ultrasound FNA: An illustrated review of spindle cell neoplasms of the upper
333 gastrointestinal tract including a novel case of gastric plexiform fibromyxoma. *Diagn*
334 *Cytopathol.* 2018 Sep;46(9):730-738. doi: 10.1002/dc.24040.
- 335 20. Hizawa K, Matsumoto T, Kouzuki T, Suekane H, Esaki M, Fujishima M. Cystic
336 submucosal tumors in the gastrointestinal tract: endosonographic findings and
337 endoscopic removal. *Endoscopy.* 2000;32:712-714.
- 338 21. Hedenström P, Marschall HU, Nilsson B, Demir A, Lindkvist B, Nilsson O, Sadik R.
339 High clinical impact and diagnostic accuracy of EUS-guided biopsy sampling of
340 subepithelial lesions: a prospective, comparative study. *Surg Endosc.* 2018
341 Mar;32(3):1304-1313. doi: 10.1007/s00464-017-5808-2.
- 342 22. Okasha HH, Naguib M, El Nady M, Ezzat R, Al-Gemeie E, Al-Nabawy W, Aref W,
343 Abdel-Moaty A, Essam K, Hamdy A. Role of endoscopic ultrasound and
344 endoscopic-ultrasound-guided fine-needle aspiration in endoscopic biopsy negative

- 345 gastrointestinal lesions. *Endosc Ultrasound*. 2017 May-Jun;6(3):156-161. doi:
346 10.4103/2303-9027.201086.
- 347 23. Ishii M, Takeno S, Nishida T, Nanashima A, Kubota Y, Kawakami H, Umekita Y,
348 Akiyama Y. Thoracoscopic enucleation in the left decubitus position for leiomyoma
349 of the upper thoracic esophagus: Utility of preoperative diagnosis applying
350 endoscopic ultrasound-guided fine needle aspiration. *Int J Surg Case Rep*.
351 2017;34:49-55. doi: 10.1016/j.ijscr.2017.03.007.
- 352 24. Arantes V, Logroño R, Faruqi S, Ahmed I, Waxman I, Bhutani MS. Endoscopic
353 sonographically guided fine-needle aspiration yield in submucosal tumors of the
354 gastrointestinal tract. *J Ultrasound Med*. 2004;23:1141-1150.
- 355 25. Vander Noot MR, Eloubeidi MA, Chen VK, Eltoun I, Jhala D, Jhala N, Syed S,
356 Chhieng DC. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-
357 guided fine-needle aspiration biopsy. *Cancer*. 2004;102:157-163.
- 358 26. Chen VK, Eloubeidi MA. Endoscopic ultrasound-guided fine-needle aspiration of
359 intramural and extraintestinal mass lesions: diagnostic accuracy, complication
360 assessment, and impact on management. *Endoscopy*. 2005;37:984-989
- 361 27. Manno M, Soriani P, Mirante VG, Grande G, Pigò F, Conigliaro RL. Endoscopic
362 dissection of a symptomatic giant gastric leiomyoma arising from the muscularis
363 propria. *Endoscopy*. 2017 Feb;49(S 01):E141-E142. doi: 10.1055/s-0043-103402.
- 364 28. Waxman I, Saitoh Y, Raju GS, Watari J, Yokota K, Reeves AL, Kohgo Y. High-
365 frequency probe EUS-assisted endoscopic mucosal resection: a therapeutic
366 strategy for submucosal tumors of the GI tract. *Gastrointest Endosc*. 2002;55:44-49.
- 367 29. Çolak Ş, Gürbulak B, Çakar E, Bektaş H. Resection of Mucosal and Submucosal
368 Gastrointestinal Lesions and a Double Endoscope Experience. *JLS*. 2019 Jan-
369 Mar;23(1). pii: e2018.00096. doi: 10.4293/JLS.2018.00096.
- 370 30. Chiu PWY, Yip HC, Teoh AYB, Wong VWY, Chan SM, Wong SKH, Ng EKW.
371 Peroral endoscopic tumor (POET) resection for treatment of upper gastrointestinal
372 subepithelial tumors. *Surg Endosc*. 2019 Apr;33(4):1326-1333. doi:
373 10.1007/s00464-018-06627-4.
- 374 31. Jeong ES, Hong SJ, Han JP, Kwak JJ. Submucosal Tunneling Endoscopic
375 Resection of a Leiomyoma Originating from the Muscularis Propria of the Gastric
376 Cardia. *Korean J Gastroenterol*. 2015 Dec;66(6):340-4. doi:
377 10.4166/kjg.2015.66.6.340.
- 378 32. Matsuda T, Hiki N, Nunobe S, Aikou S, Hirasawa T, Yamamoto Y, Kumagai K,
379 Ohashi M, Sano T, Yamaguchi T. Feasibility of laparoscopic and endoscopic
380 cooperative surgery for gastric submucosal tumors. *Gastrointest Endosc*. 2016
381 Jul;84(1):47-52. doi: 10.1016/j.gie.2015.11.040.
- 382